|Bid||75.210 x 200|
|Ask||75.220 x 200|
|Day's Range||74.650 - 75.990|
|52 Week Range||63.760 - 82.100|
|PE Ratio (TTM)||7.93|
|Dividend & Yield||2.08 (2.82%)|
|1y Target Est||N/A|
The Fed will be overshadowed on Wednesday by the continued parade of corporate earnings coming out this week.
For the past few months, Gilead Sciences, Inc. (NASDAQ:GILD) could not fulfill the technical upside promise. Last night, GILD report earnings and the stock is spiking toward $76. Click to Enlarge Coming into the earnings, sentiment had also shifted in favor of better days to come from GILD stock, and I am one who likes to trade with the market sentiment.
Shares of Gilead Sciences (GILD) are on the rise this morning after the biotech giant reported better-than expected earnings and revenue, and raised its product-sales guidance. Gilead reported a profit of $2.56 a share, beating forecasts for $2.29, on sales of $$7.1 billion, topping analyst expectations for $6.3 billion. Gilead also said that its net product sales would come in between $24.5 billion and 25.5 billion in 2017, up from a range of $22.5 billion to $24.5 billion.